Back Home About Us

IAS 2017: Study of Gay Men Shows No Transmissions from Undetectable HIV+ Partners

A study of 343 gay couples, where one partner had HIV and the other did not, has not found a single case of HIV transmission in 16,889 acts of condomless anal sex, according to a presentation at the 9th International AIDS Society Conference on HIV Science (IAS 2017) this week in Paris.

alt

Read more:

IAS 2017: Long-Acting Cabotegravir + Rilpivirine Looks Good for Treatment at 96 Weeks

Two long-acting injectable antiretrovirals, cabotegravir and rilpivirine, administered once every 4 or 8 weeks maintained viral suppression in about 90% of people who started therapy with an undetectable viral load, according to the latest results from the LATTE-2 trial, presented at the 9th International AIDS Society Conference on HIV Science this week in Paris and published simultaneously in The Lancet.

alt

Read more:

IAS 2017: New HIV Infections Halved in 5 Years as Treatment Scales Up in Swaziland

New HIV infections have been cut in half in Swaziland since 2011, at the same time as the proportion of people on antiretroviral treatment with fully suppressed viral load has doubled, according to a report at the 9th International AIDS Society Conference on HIV Science (IAS 2017) this week in Paris. It is the first direct evidence that expanding HIV treatment results in fewer HIV infections in a country with a major epidemic, researchers said.

alt

Read more:

IAS 2017: New HIV Integrase Inhibitor Bictegravir Works Well for First-Line Treatment

A single-tablet regimen containing the experimental integrase inhibitor bictegravir was as effective as 2 widely used approved regimens for first-time therapy in a pair of Phase 3 clinical trials, according to presentations at the 9th International AIDS Society Conference on HIV Science (IAS 2017) this week in Paris.

alt

Read more:

IAS 2017: PrEP Still Protected People Who Had Less Sex in Ipergay Study

A sub-study of the French Ipergay trial of "on-demand" pre-exposure prophylaxis (PrEP) has found that PrEP was just as effective for participants who had sex less often than average, and so took PrEP less often, as long as they did take it when it was needed. The analysis was presented by trial statistician Guillemette Antoni at the 9th International AIDS Society Conference (IAS 2017) conference this week in Paris.

alt

Read more:

IAS 2017: World On Track To Reach 90-90-90 Targets for HIV Treatment by 2020

The world is on track to reach global targets for reducing AIDS deaths and expanding HIV treatment access by 2020, but some regions of the world risk falling further behind due to lack of political commitment, UNAIDS announced in the run-up tothe 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris.

alt

Read more:

IAS 2017: South African Child Has Controlled HIV Off Treatment for 8.5 Years

A 9-year-old South African child who was diagnosed with HIV infection at 1 month of age and received HIV treatment for 40 weeks during infancy has suppressed the virus without anti-HIV drugs for 8 and a half years, scientists reported this week at the 9th IAS Conference on HIV Science (IAS 2017) in Paris.

alt

Read more:

IAS 2017: Long-Acting Cabotegravir Shows Promise For HIV Prevention

A long-acting injectable formulation of cabotegravir given every 8 weeks produces high enough drugs levels in both men and women to offer protection against HIV, according to results from the HPTN 077 study presented this week at the 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris. But another injectable prevention candidate, long-acting rilpivirine, has been abandoned.

alt

Read more:

IAS 2017: TAG Releases Annual HIV, Hepatitis C, and TB Pipeline Report

On July 18 the Treatment Action Group (TAG) announced the launch of its latest overview of investigational therapies for HIV, hepatitis C virus (HCV), and tuberculosis (TB).

alt

Read more: